ALVAL.PA - Valbiotis SA
| Previous Close | 2.2000 |
| Open | 2.3000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 2.1600 - 2.3000 |
| 52 Week Range | 1.9800 - 4.2517 |
| Volume | 24,861 |
| Avg. Volume | 11,182 |
| Market Cap | 9.1M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3950 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.75 |
- Simply Wall St.
How Much Of Valbiotis SA (EPA:ALVAL) Do Insiders Own?
A look at the shareholders of Valbiotis SA (EPA:ALVAL) can tell us which group is most powerful. Large companies...
- Simply Wall St.
Valbiotis SA (EPA:ALVAL): Is Breakeven Near?
Valbiotis SA's (EPA:ALVAL): Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and...
- Simply Wall St.
Investors Who Bought Valbiotis (EPA:ALVAL) Shares A Year Ago Are Now Down 43%
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
- Business Wire
VALBIOTIS Participates in the First HealthTech Investor Days, Organized by France Biotech
VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible) (ALVAL.PA), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced that it has been selected to participate in the first HealthTech Investor Days, being held June 24-25 in Paris. This international event is organized by France Biotech, the association of health entrepreneurs, and gathers the full ecosystem of innovation: French and European HealthTech flagships (biotechs, medtechs, e-health companies), pharmaceutical companies and international investors specialized in health innovation. This event is placed under the High Patronage of Emmanuel MACRON, President of the French Republic.
- Simply Wall St.
How Valbiotis SA (EPA:ALVAL) Can Impact Your Portfolio Volatility
If you're interested in Valbiotis SA (EPA:ALVAL), then you might want to consider its beta (a measure of share price...
- Business Wire
VALBIOTIS to Present Novel Data about TOTUM-63 and Metabolic Diseases Prevention at the 2019 Scientific Sessions of the American Diabetes Association
TOTUM-63 reduces inflammation in visceral adipose tissue, one of the mechanisms leading to type 2 diabetes and metabolic diseases. The efficacy of TOTUM-63 on sugar and lipid metabolism is confirmed in a murine model of prediabetes. These results were obtained by an independent study led by Dr. Bruno GUIGAS at Leiden University (Netherlands).
- Business Wire
VALBIOTIS Succeeds in the Industrial Production of VALEDIA®, a Major Scientific Innovation for Prediabetic People, in Collaboration with the Pierre Fabre Group
- Confirmation of VALBIOTIS's capacity to produce VALEDIA® in compliance with North American and European industrial standards. - An accomplishment due to the combined expertise of VALBIOTIS and the Pierre Fabre Group, which specializes in the industrial manufacture of plant-based products. VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the successful industrial production of VALEDIA® (active substance TOTUM-63), the most advanced product in the VALBIOTIS portfolio.
- Business Wire
VALBIOTIS Will Present the Results of the International Phase IIA Clinical Study of VALEDIA® before 31 July 2019
VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible) (ALVAL.PA), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the completion of the international Phase IIA clinical study evaluating VALEDIA® in prediabetic subjects, after the final follow-up visit was conducted with the last patient. VALBIOTIS will present the results of this study before 31 July 2019.
- Business Wire
VALBIOTIS Strengthens Its Supervisory Board with the Appointment of Agnès TIXIER
VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the appointment of Agnès TIXIER to the Supervisory Board. “Agnès TIXIER has the ideal background to support VALBIOTIS in its growth.
- Business Wire
VALBIOTIS reports exclusive data on the prediabetes market: a considerable potential for VALEDIA®
VALBIOTIS (ALVAL.PA) (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today reported exclusive data on the prediabetes market, arising from an exclusive study conducted by AEC Partners in the United States, Canada and in 5 leading European countries (Germany, United Kingdom, France, Spain and Italy).
- Business Wire
VALBIOTIS Obtains the European Patent for VALEDIA®
• VALEDIA® now holds industrial property rights for the two major global markets: Europe and the United States. VALBIOTIS (ALVAL.PA) (FR0013254851 - ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the obtention of the European patent for TOTUM-63.1 This patent directly covers the active substance of VALEDIA® for use in 38 European countries on the prediabetes and metabolic diseases market, including type 2 diabetes and NAFLD.
- Business Wire
VALBIOTIS Strengthens its Board of Directors with the Appointment of Murielle CAZAUBIEL
Regulatory News:
- Business Wire
VALBIOTIS Appoints Josep INFESTA, International Expert in Consumer Healthcare, Head of Global Business Development
VALBIOTIS (FR0013254851 - ALVAL / eligible PEA/PME), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the appointment of Josep INFESTA as Head of Global Business Development1.
